Company intelligence / Profile preview
Kangstem Biotech
- Ownership
- Private
- Employees
- ~75
- Development stage
- Preclinical
Overview
Kangstem Biotech is a South Korean biotech company specializing in the development of allogeneic umbilical cord blood-derived mesenchymal stem cell therapies. Its lead asset, FureStem AD for atopic dermatitis, is currently undergoing a pivotal Phase III trial after an initial unsuccessful study prompted clinical redesign. Other pipeline assets include FureStem RA for rheumatoid arthritis and FureStem CD for Crohn’s disease—both at earlier clinical stages. The company also develops platforms for hair loss treatment based on hair follicle organoids and offers contract manufacturing services.
- Therapeutic areas
- GastroenterologyDermatologyRheumatologyImmunology
- Modalities
- Mesenchymal stem cell therapies (primarily umbilical cord blood-derived MSCs)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Kangstem Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangstem Biotech.